Recently, checkpoint inhibitors PD-1 and CTLA-4 have been used as therapeutic targets for immune disorders, tumors (47), autoimmune diseases (20) and neuroinflammatory diseases such as Alzheimer’s disease (19). This evidence concerns the gene PDCD1 and early-onset autosomal dominant Alzheimer disease.